Overview

A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Status:
Not yet recruiting

Trial end date:
2024-09-19

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to investigate the safety and tolerability of ixekizumab in participants in India with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA)

Phase:

Phase 4

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Ixekizumab